Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

Bruno Dubois; Harald Hampel; Howard H. Feldman; Philip Scheltens; Paul Aisen; Sandrine Andrieu; Hovagim Bakardjian; Habib Benali; Lars Bertram; Kaj Blennow; Karl Broich; Enrica Cavedo; Sebastian Crutch; Jean François Dartigues; Charles Duyckaerts; Stéphane Epelbaum; Giovanni B. Frisoni; Serge Gauthier; Remy Genthon; Alida A. Gouw; Marie Odile Habert; David M. Holtzman; Miia Kivipelto; Simone Lista; José Luis Molinuevo; Sid E. O'Bryant; Gil D. Rabinovici; Christopher Rowe; Stephen Salloway; Lon S. Schneider; Reisa Sperling; Marc Teichmann; Maria C. Carrillo; Jeffrey Cummings; Cliff R. Jack

doi:10.1016/j.jalz.2016.02.002

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

Bruno Dubois^*, Harald Hampel, Howard H. Feldman, Philip Scheltens, Paul Aisen, Sandrine Andrieu, Hovagim Bakardjian, Habib Benali, Lars Bertram, Kaj Blennow, Karl Broich, Enrica Cavedo, Sebastian Crutch, Jean François Dartigues, Charles Duyckaerts, Stéphane Epelbaum, Giovanni B. Frisoni, Serge Gauthier, Remy Genthon, Alida A. GouwMarie Odile Habert, David M. Holtzman, Miia Kivipelto, Simone Lista, José Luis Molinuevo, Sid E. O'Bryant, Gil D. Rabinovici, Christopher Rowe, Stephen Salloway, Lon S. Schneider, Reisa Sperling, Marc Teichmann, Maria C. Carrillo, Jeffrey Cummings, Cliff R. Jack

^*Corresponding author for this work

Institute of Neurogenetics

1570 Citations (Scopus)

Abstract

During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this "silent" stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.

Original language	English
Journal	Alzheimer's and Dementia
Volume	12
Issue number	3
Pages (from-to)	292-323
Number of pages	32
ISSN	1552-5260
DOIs	https://doi.org/10.1016/j.jalz.2016.02.002
Publication status	Published - 01.03.2016

Funding

H.H. is supported by the AXA Research Fund , the Fondation Université Pierre et Marie Curie , and the “Fondation pour la Recherche sur Alzheimer” , Paris, France. The research leading to these results has received funding from the program “ Investissements d'avenir ” ANR-10-IAIHU-06. S.L. is supported by the European Medical Information Framework (EMIF). R.S. is supported by the National Institute on Aging and Alzheimer's Association . The authors acknowledge the helpful contribution of Zaven Khachaturian as an advisor to the Working Group in charge of the article. The meeting was supported by the French International Foundation for Research in Alzheimer's disease (IFRAD).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jalz.2016.02.002

Cite this

Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., Broich, K., Cavedo, E., Crutch, S., Dartigues, J. F., Duyckaerts, C., Epelbaum, S., Frisoni, G. B., Gauthier, S., Genthon, R., ... Jack, C. R. (2016). Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's and Dementia, 12(3), 292-323. https://doi.org/10.1016/j.jalz.2016.02.002

@article{a8719a0361344985b51384f3a4262d3a,

title = "Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria",

abstract = "During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this {"}silent{"} stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.",

author = "Bruno Dubois and Harald Hampel and Feldman, \{Howard H.\} and Philip Scheltens and Paul Aisen and Sandrine Andrieu and Hovagim Bakardjian and Habib Benali and Lars Bertram and Kaj Blennow and Karl Broich and Enrica Cavedo and Sebastian Crutch and Dartigues, \{Jean Fran{\c c}ois\} and Charles Duyckaerts and St{\'e}phane Epelbaum and Frisoni, \{Giovanni B.\} and Serge Gauthier and Remy Genthon and Gouw, \{Alida A.\} and Habert, \{Marie Odile\} and Holtzman, \{David M.\} and Miia Kivipelto and Simone Lista and Molinuevo, \{Jos{\'e} Luis\} and O'Bryant, \{Sid E.\} and Rabinovici, \{Gil D.\} and Christopher Rowe and Stephen Salloway and Schneider, \{Lon S.\} and Reisa Sperling and Marc Teichmann and Carrillo, \{Maria C.\} and Jeffrey Cummings and Jack, \{Cliff R.\}",

year = "2016",

month = mar,

day = "1",

doi = "10.1016/j.jalz.2016.02.002",

language = "English",

volume = "12",

pages = "292--323",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "John Wiley and Sons Inc",

number = "3",

}

Dubois, B, Hampel, H, Feldman, HH, Scheltens, P, Aisen, P, Andrieu, S, Bakardjian, H, Benali, H, Bertram, L, Blennow, K, Broich, K, Cavedo, E, Crutch, S, Dartigues, JF, Duyckaerts, C, Epelbaum, S, Frisoni, GB, Gauthier, S, Genthon, R, Gouw, AA, Habert, MO, Holtzman, DM, Kivipelto, M, Lista, S, Molinuevo, JL, O'Bryant, SE, Rabinovici, GD, Rowe, C, Salloway, S, Schneider, LS, Sperling, R, Teichmann, M, Carrillo, MC, Cummings, J & Jack, CR 2016, 'Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria', Alzheimer's and Dementia, vol. 12, no. 3, pp. 292-323. https://doi.org/10.1016/j.jalz.2016.02.002

TY - JOUR

T1 - Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

AU - Dubois, Bruno

AU - Hampel, Harald

AU - Feldman, Howard H.

AU - Scheltens, Philip

AU - Aisen, Paul

AU - Andrieu, Sandrine

AU - Bakardjian, Hovagim

AU - Benali, Habib

AU - Bertram, Lars

AU - Blennow, Kaj

AU - Broich, Karl

AU - Cavedo, Enrica

AU - Crutch, Sebastian

AU - Dartigues, Jean François

AU - Duyckaerts, Charles

AU - Epelbaum, Stéphane

AU - Frisoni, Giovanni B.

AU - Gauthier, Serge

AU - Genthon, Remy

AU - Gouw, Alida A.

AU - Habert, Marie Odile

AU - Holtzman, David M.

AU - Kivipelto, Miia

AU - Lista, Simone

AU - Molinuevo, José Luis

AU - O'Bryant, Sid E.

AU - Rabinovici, Gil D.

AU - Rowe, Christopher

AU - Salloway, Stephen

AU - Schneider, Lon S.

AU - Sperling, Reisa

AU - Teichmann, Marc

AU - Carrillo, Maria C.

AU - Cummings, Jeffrey

AU - Jack, Cliff R.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this "silent" stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.

AB - During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this "silent" stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.

UR - https://www.scopus.com/pages/publications/84962325429

U2 - 10.1016/j.jalz.2016.02.002

DO - 10.1016/j.jalz.2016.02.002

M3 - Journal articles

C2 - 27012484

AN - SCOPUS:84962325429

SN - 1552-5260

VL - 12

SP - 292

EP - 323

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 3

ER -

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

Abstract

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this